quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:00:00·482d
PRRelease
BeiGene Ltd. logo

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

BGNE· BeiGene Ltd.
Health Care
Original source

Companies

  • BGNE
    BeiGene Ltd.
    Health Care

Recent analyst ratings

  • Dec 3UpdateMorgan Stanley$300.00
  • Sep 18UpdateJMP Securities$288.00
  • Feb 6UpdateJP Morgan$185.00
  • Sep 12UpdateMacquarie$259.00
  • Aug 17UpdateJefferies$287.00
  • Jul 17UpdateCitigroup$275.00

Related

  • PR388d
    BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
  • SEC486d
    BeiGene Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR486d
    BeiGene to Change Nasdaq Ticker Symbol to "ONC" on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
  • INSIDER492d
    Chief Executive Officer Oyler John exercised 1,300,000 units of Ordinary Shares at a strike of $0.50, increasing direct ownership by 77% to 2,978,833 units (SEC Form 4)
  • PR497d
    BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
  • INSIDER497d
    Chair, Scientific Advisory Brd Wang Xiaodong sold $7,805,106 worth of American Depositary Shares (41,760 units at $186.90) and exercised 41,760 units of American Depositary Shares at a strike of $6.50 (SEC Form 4)
  • 13D/G499d
    Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.
  • INSIDER499d
    Director Baker Bros. Advisors Lp sold $194,200,043 worth of American Depositary Shares (1,037,017 units at $187.27) (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022